Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. The company's mission is to protect and save lives by developing, manufacturing, and delivering solutions that address accidental, intentional, and naturally occurring public health threats. It focuses on providing critical medical countermeasures and specialty products for various public health challenges.

Emergent BioSolutions offers a diverse portfolio of products, including NARCAN Nasal Spray for opioid overdose emergencies, BioThrax and CYFENDUS for anthrax, ACAM2000 and TEMBEXA for smallpox and mpox, and Ebanga for Ebola. The company also provides vaccines for infectious diseases such as cholera (Vaxchora) and typhoid fever (Vivotif). Beyond its proprietary products, Emergent BioSolutions provides Contract Development and Manufacturing Organization (CDMO) services to other biopharmaceutical companies. Its primary customers for medical countermeasures are government agencies, particularly in the U.S. and allied nations, while commercial and public interest channels are targeted for products like NARCAN.

Joseph C. Papa serves as the President and CEO of Emergent BioSolutions. In the first quarter of 2026, the company reported revenues of $156.1 million and a net income of $6.8 million. Recent strategic initiatives include securing new manufacturing partnerships with SAB Biotherapeutics and Substipharm Biologics, and refinancing its term loan to enhance financial flexibility. Emergent BioSolutions has also expanded its efforts in opioid overdose preparedness, partnering with British Columbia to supply NARCAN Nasal Spray for their Take-Home Naloxone Program and launching new carrying cases and multipacks for the product. The company maintains a leading market position in specialized biopharmaceuticals, particularly in medical countermeasures and naloxone, supported by strong relationships with government entities.